Q4-2012. gmsbiotech is pleased to announce that Mr.
Milan Patel has joined as CFO & Alan Jernigan as SVP of Sales & Marketing.
Prior to joining GMSBiotech Mr. Patel served as Chief Financial Officer of 2020
Company, LLC- a leading professional services firm that delivered business and
technology solutions to the government, in the areas of health, education and
science. Alan Jernigan has held previous
senior level positions in prestigious companies such as One Lambda, a leader in
Transplant Diagnostics, where he was their Chief Marketing Officer.
gmsbiotech has secured private funding to accelerate HLA Product
Launch and FDA 510(k) submission.
gmsbiotech has received Letter of Certification as a Qualified
Small Business for the Small Business Capital Investment Incentive Program from
Arizona Commerce Authority.
May 2012. gmsbiotech received a US patent (No. 8,183,360) on
Population Scale HLA-Typing and Uses Thereof on May 22, 2012.
Dr. Krishna Jayaraman President & CEO was invited to make a presentation
and to be a panel member in the 14th Annual SBIR/STTR Conference held in
Louisville, Kentucky (May 30th-June 1st)
April 2012. gmsbioetch received a two year R21grant from National
Heart Blood and Lung Institute for High-Throughput HLA-Typing: on Raw, Unpurified
Cord Blood Samples. gmsbiotech will have access to archived cord blood samples
An article on this grant award appeared in Genomeweb News (May 10, 2012)
October 2011. gmsbiotech made a poster presentation at the 37th
Annual Meeting of ASHI held in New Orleans from October 17th -21st. The title
of the presentation was ”High-Throughput HLA Typing Via Touch Rehydration of
Dried Blood On Guthrie Cards”.
September 2011. Dr. Nutan Dighe, Senior Scientist from Bangalore
Medical Services Trust, India underwent a two week comprehensive training in
advanced HLA Chip Technology at gmsbiotech Tucson facility.
August 2011. gmsbiotech was awarded a Phase I SBIR grant by
National Heart, Blood and Lung Institute (NHBLI) titled "The transfusion
chip: a simple, low cost microarray for DNA-based blood typing." The grant
was awarded on Aug 1 and is set to expire on Jan. 30, 2012.
The grant will help gmsbiotech develop an array-based blood-screening device
that could replace existing serological techniques used in blood banks.
June 2011. gmsbiotech will present at Cambridge Healthtech
Institute’s The Business of Genomics: Planning to Survive and Thrive as part of
the upcoming Beyond Sequencing meeting, on June 20th 2011 in San Francisco.
gmsbiotech will present at the 13th Annual NIH SBIR/STTR Conference organized
by NIH on June 22, 2011. gmsbiotech is one of among over fifty NIH SBIR and/or
STTR Phase II awardees that will display their scientific findings at the
May 2011. gmsbiotech launched alpha testing of its HLA Chip technology
in the ASHI-certified Histocompatibility and Transplant Immunology laboratories
of The Methodist Hospital, Houston TX, under the direction of Dr. Geoffrey
Land. Dr. Land is the current President of ASHI.
gmsbiotech is listed in the NIH “Success Story” website. See under Genomics USA
at http://grants1.nih.gov/grants/funding/sbir_successes/sbir_successes.htm. The
companies listed in this website have used the SBIR/STTR funding to
successfully commercialize their products. Past inclusion in this website in
the life science category includes companies such as Illumina and NimbleGen.
April 2011. Jennifer Morgan, Ph.D., Senior Scientist from the New Zealand
Blood Services Labs completed a comprehensive 1-week training session at gmsbiotech
labs in Tucson: comprising advanced training in HLA-Chip technology and Ricimer
2011. gmsbiotech has expanded its R&D facility with the addition of
another 2000 sq. ft.of laboratory space.
November 10, 2010. Dr. Michael Hogan, The Chief Scientific Officer
of gmsbiotech, will be presenting a talk at the APHIA (Asia-Pacific Histocompatibility
& Immunogenetics Association) to be held in Queenstown, New Zealand from
16-19 November 2010 titled“Microarray-Based HLA Typing on Unpurified Samples
from Blood and Buccal Swabs”.
notification of grant award from the IRS for the Qualified Therapeutic
Discovery Project for the development of a microarray based HLA typing
technology for solid organ and marrow transplantations and as a diagnostic tool
in the personalized medicine applications.
Sepember 27, 2010.
gmsbiotech to present a talk and a poster at the annual meeting of the American
Society for Histocompatibility and Immunogentics (ASHI) in Hollywood Florida
(Sept 26-30th) entitled: “Microarray-Based HLA Typing on Unpurifed DNA Samples
from Blood and Buccal Swabs”. This is the first discussion of a new gmsbiotech
technology, to perform low cost HLA typing on raw blood, dried blood spots and
from cheek swabs,in a way that bypasses DNA purification.
August 1, 2010.gmsbiotech launched alpha testing of its HLA Chip
technology in the ASHI-certified laboratories of The New Zealand Blood Labs,
Auckland NZ, under the direction of Dr Paul Dunn. This alpha test program will
be used to validate the technology, for low cost HLA typing in the context of
routine workflow in an ASHI-certified tissue typing laboratory.
July 1, 2010.gmsbiotech will conduct its business (DBA) in the
name of gmsbiotech (Genetics Made Simple) to reflect the simplifications
inherent in its technologies for complex, population-scale genetics.
February 23, 2010.The US Patent and Trademark Office has awarded
gmsbiotech a patent: Hogan ME, Jayaraman K, Mitra R & Eggers RH. Population
Scale HLA Typing and Methods Thereof. US Patent No. 7,667,026. This US patent
confirms broad protection to the design of its HLA-Chip products.
November 3, 2009.gmsbiotech presented its HLA-Chip technology at
the 35th annual meeting of The American Society of Histocompatibility and
Immunogenetics (ASHI). This appearance was a springboard event for gmsbiotech
to obtain ASHI certification of its HLA-Chip technology. The HLA-Chip product
consists of gene probes for the analysis of genetic compatibility in marrow,
stem cell& solid organ transplantation: the well-known backbone of
August 15, 2009.The National Institute of Allergy and Infectious
Disease has awarded a three year, Phase II SBIR Competitive Continuation grant
to gmsbiotech, to support ASHI & FDA approval of its "HLA-Chip"
Product for low cost, population-scale HLA-typing. This Phase II Continuation
Grant award is significant, in that such programs must have already completed a
successful Phase II, and the resulting product must stand ready, during the
three-year Continuation Phase, for validation and approval by a Federal
regulatory agency such as the FDA.
August 15, 2009.The National Institute of Allergy and Infectious
Disease has awarded a two year, Phase I Advanced Technology SBIR grant to
gmsbiotech, to support development of an "AIDS-Chip" to be used for
population scale analysis of the personalized risk of HIV infection and
personalized response to AIDS therapy, based on variation in the human immune
system. This product development program is an important milestone for gmsbiotech,
in that it parallels the company's move into the personalized genetic medicine
of vaccines and chemical therapeutics.
July 2009. Dr. Kamala Balakrishnan has joined the company as an Advisor
Q3-2008. gmsbiotech received a Notice of Intent to grant the European patent
application No. 02748133.2 titled “Methods and Devices Based Upon A Novel Form
of Nucleic Acid Duplex On A Surface”.
Q3-2008. Dr. Paul Dunn, Director of HLA typing lab of NewZealand Blood
Services, Auckland, has joined the gmsbiotech team as ASHI Director and HLA
April 8, 2008.The US Patent and Trademark Office has awarded to
gmsbiotech, the US Patent 7,354,710, "Methods and devices based upon a
novel form of the nucleic acid duplex on a surface". This patent comprises
an important base for the gmsbiotech technology platform.
Q3-2006. gmsbiotech receives funding of about $3 million for 3 years
effective from September 1, 2006 for its Phase 2 grant "Population-scale
HLA typing for home land defense.
Q2-2006. gmsbiotech receives funding from QuantRx BioMedical Corporation.
Q2-2004.gmsbiotech’s SBIR Phase I grant "Population-scale HLA
typing for home land defense," is funded by NIAID, effective May 1, 2004.
Q3-2003. gmsbiotech is awarded a seed grant from Chicago ITEC to
continue its feasibility studies.